Neuroendocrine tumor disease: An evolving landscape

Endocrine-Related Cancer

Volumn 19, Issue 5, 2012, Pages

  Frilling, Andrea ^a   Åkerström, Goran ^b   Falconi, Massimo ^c   Pavel, Marianne ^d   Ramos, Jose ^e   Kidd, Mark ^f   Modlin, Irvin Mark ^f  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF VERONA   (Italy)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CHROMOGRANIN A; CYCLOPHOSPHAMIDE; DALOTUZUMAB; EVEROLIMUS; GEFITINIB; IMATINIB; KI 67 ANTIGEN; MOTESANIB; OCTREOTIDE; PASIREOTIDE; PAZOPANIB; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SORAFENIB; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; VASCULOTROPIN ANTIBODY;

ANTIPROLIFERATIVE ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURGERY; DELAYED DIAGNOSIS; DRUG EFFICACY; GASTRIC NEUROENDOCRINE TUMOR; GASTRINOMA; GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASM; GLUCAGONOMA; HUMAN; INSULINOMA; LIVER METASTASIS; LYMPH NODE METASTASIS; MIDGUT NEUROENDOCRINE TUMOR; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; TUMOR ABLATION; VIPOMA;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867413693     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0024     Document Type: Review

References (159)

1. Akerstrom G & Hellman P 2009 Surgical aspects of neuroendocrine tumours. European Journal of Cancer 45 (Suppl 1) 237-250. (doi:10.1016/S0959- 8049(09)70039-5)
2. Akerstrom G, Hellman P, Hessman O & Osmak L 2004 Surgical treatment of endocrine pancreatic tumours. Neuroendocrinology 80 62-66. (doi:10.1159/000080744)
3. Åkerström G, Hellman P & Hessman O 2009 Gastrointestinal carcinoids. In Endocrine Surgery, 4th edn, pp 147-176. Ed T Lennard. London: Saunders Elsevier.
4. Aranha GV & Shoup M 2005 Nonstandard pancreatic resections for unusual lesions. American Journal of Surgery 189 223-228. (doi:10.1016/j. amjsurg.2004.11.005)
5. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jurgensen R, Stein K, Schafer H, Bruns C et al. 1996 Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 38 430-438. (doi:10.1136/gut.38.3.430)
6. Arnold CN, Nagasaka T, Goel A, Scharf I, Grabowski P, Sosnowski A, Schmitt-Graff A, Boland CR, Arnold R & Blum HE 2008a Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors. International Journal of Cancer 123 1556-1564. (doi:10.1002/ijc.23690)
7. Arnold R, Wilke A, Rinke A, Mayer C, Kann PH, Klose KJ, Scherag A, Hahmann M, Muller HH & Barth P 2008b Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clinical Gastroenterology and Hepatology 6 820-827. (doi:10.1016/j.cgh.2008.02. 052)
8. Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G et al. 2006 Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. Cancer 107 2474-2481. (doi:10.1002/cncr.22272)
9. Bartsch DK, Schilling T, Ramaswamy A, Gerdes B, Celik I, Wagner HJ, Simon B & Rothmund M 2000 Management of nonfunctioning islet cell carcinomas. World Journal of Surgery 24 1418-1424. (doi:10.1007/s002680010234)
10. Bartsch DK, Fendrich V, Langer P, Celik I, Kann PH & Rothmund M 2005 Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Annals of Surgery 242 757-764 (discussion 764-756). (doi:10.1097/01.sla.0000189549.51913.d8)
11. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A & Falconi M 2008 Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Annals of Oncology 19 903-908. (doi:10.1093/annonc/mdm552)
12. Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli P, Scarpa A & Falconi M 2011 Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 150 75-82. (doi:10.1016/j.surg.2011.02.022)
13. Bonaccorsi-Riani E, Apestegui C, Jouret-Mourin A, Sempoux C, Goffette P, Ciccarelli O, Borbath I, Hubert C, Gigot JF, Hassoun Z et al. 2010 Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. Transplant International 23 668-678. (doi:10.1111/j.1432-2277.2010.01086.x)
14. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G & Grimelius L 2005 Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Annals of Surgery 242 64-73. (doi:10.1097/01.sla. 0000167862.52309.7d)
15. Bosman FT, Carneiro F, Hruban RH & Theise ND (Eds) 2010 WHO Classification of Tumours of the Digestive System, 4th edn. World Health Organization Press: Geneva, Switzerland.
16. Boudreaux JP, Putty B, Frey DJ, Woltering E, Anthony L, Daly I, Ramcharan T, Lopera J & Castaneda W 2005 Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Annals of Surgery 241 839-845 (discussion 845-836). (doi:10.1097/01.sla.0000164073.08093.5d)
17. Brophy C & Cahow CE 1989 Primary small bowel malignant tumors. Unrecognized until emergent laparotomy. American Surgeon 55 408-412.
18. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging 34 1617-1626. (doi:10.1007/s00259-007-0450-1)
19. Burkitt MD & Pritchard DM 2006 Review article: pathogenesis and management of gastric carcinoid tumours. Alimentary Pharmacology & Therapeutics 24 1305-1320. (doi:10.1111/j.1365-2036.2006.03130.x)
20. Campana D, Piscitelli L, Mazzotta E, Bonora M, Serra C, Salomone L, Corinaldesi R & Tomassetti P 2005 Zollinger-Ellison syndrome. Diagnosis and therapy. Minerva Medica 96 187-206.
21. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R & Tomassetti P 2008 Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocrine-Related Cancer 15 337-342. (doi:10.1677/ERC-07-0251)
22. Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G & Falconi M 2011 Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: a systematic review. Neuroendocrinology 93 223-229. (doi:10.1159/000324770)
23. Carew JS, Kelly KR & Nawrocki ST 2011 Mechanisms of mTOR inhibitor resistance in cancer therapy. Targeted Oncology 6 17-27. (doi:10.1007/s11523- 011-0167-8)
24. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC et al. 2008 Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation 118 3065-3074.
25. Cho CS, Labow DM, Tang L, Klimstra DS, Loeffler AG, Leverson GE, Fong Y, Jarnagin WR, D'Angelica MI, Weber SM et al. 2008 Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer 113 126-134. (doi:10.1002/cncr.23523)
26. Dahan L, Bonnetain F, Rougier P, Raoul JL, Gamelin E, Etienne PL, Cadiot G, Mitry E, Smith D, Cvitkovic F et al. 2009 Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocrine-Related Cancer 16 1351-1361. (doi:10.1677/ERC-09-0104)
27. Doherty GM 2005 Rare endocrine tumours of the GI tract. Best Practice & Research. Clinical Gastroenterology 19 807-817. (doi:10.1016/j.bpg.2005. 05.004)
28. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D & Chapuis Y 1996 Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World Journal of Surgery 20 908-914 (discussion 914-905). (doi:10.1007/s002689900138)
29. Drozdov I, Kidd M, Nadler B, Camp RL, Mane SM, Hauso O, Gustafsson BI & Modlin IM 2009 Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning. Cancer 115 1638-1650. (doi:10.1002/cncr.24180)
30. Ekeblad S, Skogseid B, Dunder K, Oberg K & Eriksson B 2008 Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clinical Cancer Research 14 7798-7803. (doi:10.1158/1078-0432.CCR-08-0734)
31. Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A & Gross DJ 2011 Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. Clinical Endocrinology 74 593-598. (doi:10.1111/j.1365-2265. 2011.03967.x)
32. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, Schlumberger M, Pocard M, Boige V, Miquel C et al. 2003 Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 133 375-382. (doi:10.1067/msy.2003.114)
33. Eriksson B, Renstrup J, Imam H & Oberg K 1997 High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Annals of Oncology 8 1041-1044. (doi:10.1023/A:1008205415035)
34. Falconi M, Bettini R, Boninsegna L, Crippa S, Butturini G & Pederzoli P 2006 Surgical strategy in the treatment of pancreatic neuroendocrine tumors. Journal of the Pancreas 7 150-156.
35. Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L, Capitanio V, Bassi C, Di Carlo V & Pederzoli P 2010 Parenchyma-preserving resections for small non-functioning pancreatic endocrine tumors. Annals of Surgical Oncology 17 1621-1627. (doi:10.1245/s10434-010-0949-8)
36. Falconi M, Bartsch DK, Eriksson B, Kloppel G, Lopes JM, O'Connor JM, Salazar R, Taal BG, Vullierme MP, O'Toole D et al. 2012 ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 95 120-134. (doi:10.1159/000335587)
37. Fazio N, de Braud F, Delle Fave G & Oberg K 2007 Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Annals of Oncology 18 13-19. (doi:10.1093/annonc/mdl144)
38. Fendrich V, Langer P, Waldmann J, Bartsch DK & Rothmund M 2007 Management of sporadic and multiple endocrine neoplasia type 1 gastrinomas. British Journal of Surgery 94 1331-1341. (doi:10.1002/bjs.5987)
39. Frilling A, Malago M, Weber F, Paul A, Nadalin S, Sotiropoulos GC, Cicinnati V, Beckebaum S, Bockisch A, Mueller-Brand J et al. 2006 Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transplantation 12 1089-1096. (doi:10.1002/lt.20755)
40. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A & Broelsch CE 2009 Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. British Journal of Surgery 96 175-184. (doi:10.1002/bjs.6468)
41. 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Annals of Surgery 252 850-856. (doi:10.1097/SLA. 0b013e3181fd37e8)
42. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U & Waldum HL 2004 Treatment of ECL cell carcinoids with octreotide LAR. Scandinavian Journal of Gastroenterology 39 621-628. (doi:10.1080/00365520410005225)
43. Gauger PG, Doherty GM, Broome JT, Miller BS & Thompson NW 2009 Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery 146 801-806 (discussion 807-808). (doi:10.1016/j.surg.2009.06.038)
44. Gedaly R, Daily MF, Davenport D, McHugh PP, Koch A, Angulo P & Hundley JC 2011 Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Archives of Surgery 146 953-958. (doi:10.1001/archsurg.2011.186)
45. Ghaferi AA, Chojnacki KA, Long WD, Cameron JL & Yeo CJ 2008 Pancreatic VIPomas: subject review and one institutional experience. Journal of Gastrointestinal Surgery 12 382-393. (doi:10.1007/s11605-007-0177-0)
46. Goudet P, Murat A, Binquet C, Cardot-Bauters C, Costa A, Ruszniewski P, Niccoli P, Menegaux F, Chabrier G, Borson-Chazot F et al. 2010 Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients. World Journal of Surgery 34 249-255. (doi:10.1007/s00268-009-0290-1)
47. Gupta S, Engstrom PF & Cohen SJ 2011 Emerging therapies for advanced gastroenteropancreatic neuroendocrine tumors. Clinical Colorectal Cancer 10 298-309. (doi:10.1016/j.clcc.2011.06.006)
48. Haug AR, Rominger A,Mustafa M, Auernhammer C, Goke B, Schmidt GP, Wangler B, Cumming P, Bartenstein P & Hacker M 2011 Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. Journal of Nuclear Medicine 52 1679-1683. (doi:10.2967/jnumed.111.089276)
49. Hellman P, Andersson M, Rastad J, Juhlin C, Karacagil S, Eriksson B, Skogseid B & Akerstrom G 2000 Surgical strategy for large or malignant endocrine pancreatic tumors. World Journal of Surgery 24 1353-1360. (doi:10.1007/s002680010224)
50. Hellman P, Lundstrom T, Ohrvall U, Eriksson B, Skogseid B, Oberg K, Tiensuu Janson E & Akerstrom G 2002 Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World Journal of Surgery 26 991-997. (doi:10.1007/s00268-002-6630-z)
51. Hentic O, Couvelard A, Rebours V, Zappa M, Dokmak S, Hammel P, Maire F, O'Toole D, Levy P, Sauvanet A et al. 2010 Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. Endocrine-Related Cancer 18 51-59. (doi:10.1677/ERC-09-0319)
52. Hofland LJ & Lamberts SW 1996 Somatostatin receptors and disease: role of receptor subtypes. Baillière's Clinical Endocrinology and Metabolism 10 163-176. (doi:10.1016/S0950-351X(96)80362-4)
53. Hopper AD, Bourke MJ, Hourigan LF, Tran K, Moss A & Swan MP 2009 En-bloc resection of multiple type 1 gastric carcinoid tumors by endoscopic multi-band mucosectomy. Journal of Gastroenterology and Hepatology 24 1516-1521. (doi:10.1111/j.1440-1746.2009.05909.x)
54. Imamura M, Komoto I, Doi R, Onodera H, Kobayashi H & Kawai Y 2005 New pancreas-preserving total duodenectomy technique. World Journal of Surgery 29 203-207. (doi:10.1007/s00268-004-7585-z)
55. 90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of Clinical Oncology 29 2416-2423. (doi:10.1200/JCO.2010.33.7873)
56. Jacobs C 2009 Neuroendocrine tumors a rare finding: part I. Clinical Journal of Oncology Nursing 13 21-23. (doi:10.1188/09.CJON.21-23)
57. Jann H, Roll S, Couvelard A, Hentic O, Pavel M, Muller-Nordhorn J, Koch M, Rocken C, Rindi G, Ruszniewski P et al. 2011 Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 117 3332-3341 (doi: 3310.1002/cncr.25855). (doi:10.1002/cncr. 25855)
58. Jensen RT, Berna MJ, Bingham DB & Norton JA 2008 Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 113 1807-1843. (doi:10.1002/cncr.23648)
59. Jianu CS, Fossmark R, Syversen U, Hauso O, Fykse V & Waldum HL 2011 Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scandinavian Journal of Gastroenterology 46 456-463. (doi:10.3109/00365521.2010.539255)
60. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA et al. 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331 1199-1203. (doi:10.1126/science.1200609)
61. Kaehler G, Grobholz R, Langner C, Suchan K & Post S 2006 A new technique of endoscopic full-thickness resection using a flexible stapler. Endoscopy 38 86-89. (doi:10.1055/s-2005-921181)
62. Kasajima A, Pavel M, Darb-Esfahani S, Noske A, Stenzinger A, Sasano H, Dietel M, Denkert C, Rocken C, Wiedenmann B et al. 2011 mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours. Endocrine-Related Cancer 18 181-192. (doi:10.1677/ERC-10-0126)
63. 18F-FDG. Cancer 112 2447-2455. (doi:10.1002/cncr.23469)
64. Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin M & Meyer T 2011 Circulating tumor cells and EpCAM expression in neuroendocrine tumors. Clinical Cancer Research 17 337-345. (doi:10.1158/1078- 0432.CCR-10-1776)
65. Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Levy P, Vilgrain V, Ruszniewski P & Belghiti J 2008 Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Annals of Surgery 247 659-665. (doi:10.1097/SLA.0b013e31816a7061)
66. Kidd M, Modlin IM, Mane SM, Camp RL & Shapiro MD 2006 QRT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. Annals of Surgery 243 273-280. (doi:10.1097/01.sla.0000197734.28551.0f)
67. Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, Janson ET, Welin S, Oberg K & Eriksson B 2007 Endocrine pancreatic tumors with glucagon hypersecretion: a retrospective study of 23 cases during 20 years. Medical Oncology 24 330-337. (doi:10.1007/s12032-007-0011-2)
68. 11C-5-hydroxy-tryptophan positron emission tomography. Journal of Clinical Oncology 26 1489-1495. (doi:10.1200/JCO.2007.15.1126)
69. Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE & Evans DB 2005 Surgical treatment of non-functioning pancreatic islet cell tumors. Journal of Surgical Oncology 89 170-185. (doi:10.1002/jso.20178)
70. Kouvaraki MA, Shapiro SE, Cote GJ, Lee JE, Yao JC, Waguespack SG, Gagel RF, Evans DB & Perrier ND 2006 Management of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. World Journal of Surgery 30 643-653. (doi:10.1007/s00268-006-0360-y)
71. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X et al. 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of Clinical Oncology 26 3403-3410. (doi:10.1200/JCO.2007.15.9020)
72. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS et al. 2009 O-6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clinical Cancer Research 15 338-345. (doi:10.1158/1078-0432.CCR-08-1476)
73. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J & Hahn RG 1986 Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. New England Journal of Medicine 315 663-666. (doi:10.1056/NEJM198609113151102)
74. 3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 26 2124-2130. (doi:10.1200/JCO.2007.15.2553)
75. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW & Krenning EP 2010 Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer 17 R53-R73. (doi:10.1677/ERC-09-0078)
76. Lamberts SW, Bakker WH, Reubi JC & Krenning EP 1990 Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog. Journal of Steroid Biochemistry and Molecular Biology 37 1079-1082. (doi:10.1016/0960-0760(90)90469-2)
77. La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G & Solcia E 1996 Prognostic criteria in non-functioning pancreatic endocrine tumours. Virchows Archiv 429 323-333.
78. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M & Modlin IM 2011a The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40 1-18, vii. (doi:10.1016/j.ecl.2010. 12.005)
79. Lawrence B, Gustafsson BI, Kidd M, Pavel M, Svejda B & Modlin IM 2011b The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinology and Metabolism Clinics of North America 40 111-134, viii. (doi:10.1016/j.ecl.2010.12.001)
80. Lerut JP, Weber M, Orlando G & Dutkowski P 2007 Vascular and rare liver tumors: a good indication for liver transplantation? Journal of Hepatology 47 466-475. (doi:10.1016/j.jhep.2007.07.005)
81. Le Treut YP, Gregoire E, Belghiti J, Boillot O, Soubrane O, Mantion G, Cherqui D, Castaing D, Ruszniewski P, Wolf P et al. 2008 Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. American Journal of Transplantation 8 1205-1213. (doi:10.1111/j.1600-6143.2008.02233.x)
82. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, Walsh JH, Beg M, Bochenek W & Metz DC 2000 Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 118 696-704. (doi:10.1016/S0016-5085(00)70139-9)
83. Madeira I, Terris B, Voss M, Denys A, Sauvanet A, Flejou JF, Vilgrain V, Belghiti J, Bernades P & Ruszniewski P 1998 Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43 422-427. (doi:10.1136/gut.43.3.422)
84. Maire F, Hammel P, Kianmanesh R, Hentic O, Couvelard A, Rebours V, Zappa M, Raymond E, Sauvanet A, Louvet C et al. 2009 Is adjuvant therapy with streptozotocin and 5-fluorouracil useful after resection of liver metastases from digestive endocrine tumors? Surgery 145 69-75. (doi:10.1016/j.surg.2008.08. 007)
85. Makridis C, Rastad J, Oberg K & Akerstrom G 1996 Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World Journal of Surgery 20 900-906 (discussion 907). (doi:10.1007/ s002689900137)
86. Makridis C, Ekbom A, Bring J, Rastad J, Juhlin C, Oberg K & Akerstrom G 1997 Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. Surgery 122 1075-1082. (doi:10.1016/S0039-6060(97) 90211-7)
87. Mazzaferro V, Pulvirenti A & Coppa J 2007 Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? Journal of Hepatology 47 460-466. (doi:10.1016/j.jhep.2007.07.004)
88. McDermott EW, Guduric B & Brennan MF 1994 Prognostic variables in patients with gastrointestinal carcinoid tumours. British Journal of Surgery 81 1007-1009. (doi:10.1002/bjs.1800810725)
89. Metz DC & Jensen RT 2008 Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135 1469-1492. (doi:10.1053/j.gastro.2008.05.047)
90. Mills GY 1956 The syndrome of intestinal carcinoid, pulmonary valvular stenosis and cutaneous flush. Annals of Internal Medicine 45 1213-1221.
91. Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L, Capurso G, Di Florio A, delle Fave G et al. 2010 Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Journal of Clinical Oncology 28 245-255. (doi:10.1200/JCO.2008.21.5988)
92. Modlin IM, Lye KD & Kidd M 2003 A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97 934-959. (doi:10.1002/cncr.11105)
93. Modlin IM, Kidd M, Latich I, Zikusoka MN & Shapiro MD 2005 Current status of gastrointestinal carcinoids. Gastroenterology 128 1717-1751. (doi:10.1053/j.gastro.2005.03.038)
94. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP et al. 2008 Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology 9 61-72. (doi:10.1016/S1470-2045(07) 70410-2)
95. Modlin IM, Gustafsson BI, Drozdov I, Nadler B, Pfragner R & Kidd M 2009 Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors. Annals of Surgical Oncology 16 487-498. (doi:10.1245/s10434-008-0251-1)
96. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV & Kidd M 2010a Chromogranin A - biological function and clinical utility in neuro endocrine tumor disease. Annals of Surgical Oncology 17 2427-2443. (doi:10.1245/s10434-010-1006-3)
97. Modlin IM, Gustafsson BI, Pavel M, Svejda B, Lawrence B & Kidd M 2010b A nomogram to assess small-intestinal neuroendocrine tumor ('carcinoid') survival. Neuroendocrinology 92 143-157. (doi:10.1159/000319784)
98. Modlin IM, Pavel M, KiddM& Gustafsson BI 2010c Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Alimentary Pharmacology & Therapeutics 31 169-188.
99. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG & Klaassen D 1992 Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. NewEngland Journal ofMedicine 326 519-523. (doi:10.1056/NEJM199202203260804)
100. Mooney E 1985 The flushing patient. International Journal of Dermatology 24 549-554.
101. Mortellaro VE, Hochwald SN, McGuigan JE, Copeland EM, Vogel SB & Grobmyer SR 2009 Long-term results of a selective surgical approach to management of Zollinger-Ellison syndrome in patients with MEN-1. American Surgeon 75 730-733.
102. Nikou GC, Toubanakis C, Nikolaou P, Giannatou E, Safioleas M, Mallas E & Polyzos A 2005 VIPomas: an update in diagnosis and management in a series of 11 patients. Hepatogastroenterology 52 1259-1265.
103. Norton JA 2005 Surgical treatment and prognosis of gastrinoma. Best Practice & Research. Clinical Gastroenterology 19 799-805. (doi:10.1016/j.bpg.2005.05.003)
104. Norton JA & Jensen RT 2004 Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Annals of Surgery 240 757-773. (doi:10.1097/01.sla.0000143252.02142.3e)
105. Norton JA, Fraker DL, Alexander HR, Gibril F, Liewehr DJ, Venzon DJ & Jensen RT 2006 Surgery increases survival in patients with gastrinoma. Annals of Surgery 244 410-419.
106. Oberg K 2010 Pancreatic endocrine tumors. Seminars in Oncology 37 594-618. (doi:10.1053/j.seminoncol.2010.10.014)
107. Ohrvall U, Eriksson B, Juhlin C, Karacagil S, Rastad J, Hellman P & Akerstrom G 2000 Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World Journal of Surgery 24 1402-1408. (doi:10.1007/ s002680010232)
108. Olausson M, Friman S, Cahlin C, Nilsson O, Jansson S, Wangberg B & Ahlman H 2002 Indications and results of liver transplantation in patients with neuroendocrine tumors. World Journal of Surgery 26 998-1004. (doi:10.1007/s00268-002-6631-y)
109. Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, Wangberg B & Ahlman H 2007 Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transplantation 13 327-333. (doi:10.1002/lt.21056)
110. O'Toole D, Grossman A, Gross D, Delle Fave G, Barkmanova J, O'Connor J, Pape UF & Plockinger U 2009 ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology 90 194-202. (doi:10.1159/000225948)
111. Pavel M, Hainsworth J, Baudin E, Peeters M, Hoersch D, Anthony L, Hoosen S, St Peter J, Jehl V & Yao J 2010 A randomized, double-blind, placebo-controlled, multicenter phase III trial of everolimus/octreotide LAR vs placebo/octreotide LAR in patients with advanced neuroendocrine tumors (NET) (Radiant-2). Annals of Oncology 21 (Suppl 8) 853. Abstract LBA8.
112. Pellikka PA,Tajik AJ, Khandheria BK, Seward JB, Callahan JA, Pitot HC & Kvols LK 1993 Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients. Circulation 87 1188-1196.
113. Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S & Baum RP 2010 Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. European Journal of Nuclear Medicine and Molecular Imaging 37 67-77. (doi:10.1007/s00259-009-1205-y)
114. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, Corrie P, Davar J, Davies AH, Lewington V et al. 2012 Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 61 6-32. (doi:10.1136/gutjnl-2011-300831)
115. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A et al. 2011a Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 364 501-513. (doi:10.1056/NEJMoa1003825)
116. Raymond E, Niccoli P, Raoul J, Bang Y, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A et al. 2011b Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). Journal of Clinical Oncology 29.
117. Reubi JC, Eisenwiener KP, Rink H, Waser B & Macke HR 2002 A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. European Journal of Pharmacology 456 45-49. (doi:10.1016/S0014- 2999(02)02651-1)
118. Ricci S, Antonuzzo A, Galli L, Ferdeghini M, Bodei L, Orlandini C & Conte PF 2000 Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide. Annals of Oncology 11 1127-1130. (doi:10.1023/A:1008383132024)
119. Richards ML, Gauger P, Thompson NW & Giordano TJ 2004 Regression of type II gastric carcinoids in multiple endocrine neoplasia type 1 patients with Zollinger-Ellison syndrome after surgical excision of all gastrinomas. World Journal of Surgery 28 652-658. (doi:10.1007/s00268-004-7345-0)
120. Rindi G, Falconi M, Klersy C, Albarello L, Boninsegna L, Buchler MW, Capella C, Caplin M, Couvelard A, Doglioni C et al. 2012 TNM staging of neoplasms of the endocrine pancreas: results from a large International Cohort Study. Journal of the National Cancer Institute 104 764-777. (doi:10.1093/jnci/djs208)
121. Ringertz N 1967 The gastrointestinal carcinoid and the carcinoid syndrome. National Cancer Institute Monographs 25 299-315.
122. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Blaker M et al. 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology 27 4656-4663. (doi:10.1200/JCO.2009.22.8510)
123. Robiolio PA, Rigolin VH, Wilson JS, Harrison JK, Sanders LL, Bashore TM & Feldman JM 1995 Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 92 790-795.
124. Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, Lang H, Klempnauer J, Manns MP & Boeker KH 2002 Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 73 386-394. (doi:10.1097/00007890-200202150-00012)
125. Ruszniewski P, Delle Fave G, Cadiot G, Komminoth P, Chung D, Kos-Kudla B, Kianmanesh R, Hochhauser D, Arnold R, Ahlman H et al. 2006 Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 84 158-164. (doi:10.1159/ 000098007)
126. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM & Que FG 2003 Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. Journal of the American College of Surgeons 197 29-37. (doi:10.1016/S1072-7515(03)00230-8)
127. Saxena A, Chua TC, Bester L, Kokandi A & Morris DL 2010 Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Annals of Surgery 251 910-916. (doi:10.1097/SLA.0b013e3181d3d24a)
128. Schimmack S, Svejda B, Lawrence B, Kidd M & Modlin IM 2011 The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbeck's Archives of Surgery 396 273-298. (doi:10.1007/s00423-011-0739-1)
129. Scigliano S, Lebtahi R,Maire F, Stievenart JL, Kianmanesh R, Sauvanet A, Vullierme MP, Couvelard A, Belghiti J, Ruszniewski P et al. 2009 Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. Endocrine-Related Cancer 16 977-990. (doi:10.1677/ERC-08-0247)
130. Sieren LM, Collins JN, Weireter LJ, Britt RC, Reed SF, Novosel TJ & Britt LD 2010 The incidence of benign and malignant neoplasia presenting as acute appendicitis. American Surgeon 76 808-811.
131. Smith SL, Branton SA, Avino AJ, Martin JK, Klingler PJ, Thompson GB, Grant CS & van Heerden JA 1998 Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature. Surgery 124 1050-1055. (doi:10.1067/msy.1998.92005)
132. Srirajaskanthan R, Shah T, Watkins J, Marelli L, Khan K & Caplin ME 2010 Expression of the HER-1-4 family of receptor tyrosine kinases in neuroendocrine tumours. Oncology Reports 23 909-915. (doi:10.3892/or-00000714)
133. Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, Lopes JM, Perren A, Nikou G, Yao J et al. 2008 Consensus guidelines for the management of patients with liver metastases from digestive (neuro)-endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87 47-62. (doi:10.1159/000111037)
134. 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor. Langenbeck's Archives of Surgery 395 185-192. (doi:10.1007/s00423-009-0520-x)
135. Stokkel MP, Rietbergen DD, Korse CM & Taal BG 2011 Somatostatin receptor scintigraphy and chromogranin A assay in staging and follow-up of patients with well-differentiated neuroendocrine tumors. Nuclear Medicine Communications 32 731-737. (doi:10.1097/MNM.0b013e328347a895)
136. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J & Kvols L 2011 First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117 268-275. (doi:10.1002/cncr.25425)
137. Sun W, Lipsitz S, Catalano P, Mailliard JA & Haller DG 2005 Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. Journal of Clinical Oncology 23 4897-4904. (doi:10.1200/JCO.2005.03.616)
138. Surveillance Epidemiology aERPwscg 2009 SEER*Stat Database. In Incidence - SEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases, Nov 2008 Sub (1973-2006 varying) - Linked To County Attributes - Total U.S., 1969-2006 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch.
139. Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R & Modlin IM 2011 Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Cancer 117 4141-4154. (doi:10.1002/cncr.26011)
140. Taylor JE, Theveniau MA, Bashirzadeh R, Reisine T & Eden PA 1994 Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: evidence for SSTR2 heterogeneity. Peptides 15 1229-1236. (doi:10.1016/0196-9781(94)90146-5)
141. Thompson NW 1998 Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. Journal of Internal Medicine 243 495-500. (doi:10.1046/j.1365-2796.1998.00307.x)
142. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R & Gullo L 2000 Treatment of type II gastric carcinoid tumors with somatostatin analogues. New England Journal of Medicine 343 551-554. (doi:10.1056/ NEJM200008243430805)
143. Tonelli F, Fratini G, Nesi G, Tommasi MS, Batignani G, Falchetti A & Brandi ML 2006 Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Annals of Surgery 244 61-70. (doi:10.1097/01.sla.0000218073.77254.62)
144. Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J & Caplin ME 2009 Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR. Alimentary Pharmacology & Therapeutics 30 733-740. (doi:10.1111/j.1365-2036.2009.04083.x)
145. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD & Pitt HA 2005 Neuroendocrine hepatic metastases: does aggressive management improve survival? Annals of Surgery 241 776-783 (discussion 783-775). (doi:10.1097/01.sla.0000161981.58631.ab)
146. Triponez F & Cadiot G 2007 Non-functioning tumours of the pancreas in MEN1 patients. Journal of Gastrointestinal and Liver Diseases 16 295-296.
147. Triponez F, Dosseh D, Goudet P, Cougard P, Bauters C, Murat A, Cadiot G, Niccoli-Sire P, Chayvialle JA, Calender A et al. 2006 Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Annals of Surgery 243 265-272. (doi:10.1097/01.sla.0000197715.96762.68)
148. Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C et al. 2010 Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. British Journal of Cancer 102 1106-1112. (doi:10.1038/sj.bjc.6605618)
149. Vagefi PA, Razo O, Deshpande V, McGrath DJ, Lauwers GY, Thayer SP, Warshaw AL & Fernandez-Del Castillo C 2007 Evolving patterns in the detection and outcomes of pancreatic neuroendocrine neoplasms: the Massachusetts General Hospital experience from 1977 to 2005. Archives of Surgery 142 347-354. (doi:10.1001/archsurg.142.4.347)
150. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ & Hobday TJ 2006 Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transplantation 12 448-456. (doi:10.1002/lt.20702)
151. Wangberg B, Westberg G, Tylen U, Tisell L, Jansson S, Nilsson O, Johansson V, Schersten T & Ahlman H 1996 Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World Journal of Surgery 20 892-899 (discussion 899). (doi:10.1007/s002689900136)
152. Welin S, Fjallskog ML, Saras J, Eriksson B & Janson ET 2006 Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors. Neuroendocrinology 84 42-48. (doi:10.1159/000096294)
153. Wilson JM, Melvin DB, Gray GF & Thorbjarnarson B 1974 Primary malignancies of the small bowel: a report of 96 cases and review of the literature. Annals of Surgery 180 175-179. (doi:10.1097/00000658-197408000- 00008)
154. Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJ, Fiasse RH, Valimaki MJ, Renstrup J, de Vries EG & Oberg KE 1999 Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. Journal of Clinical Oncology 17 1111.
155. Yamada Y, Post SR, Wang K, Tager HS, Bell GI & Seino S 1992 Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. PNAS 89 251-255. (doi:10.1073/pnas.89.1.251)
156. Yang Z, Tang LH & Klimstra DS 2011 Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. American Journal of Surgical Pathology 35 853-860. (doi:10.1097/PAS. 0b013e31821a0696)
157. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A et al. 2008 One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 26 3063-3072. (doi:10.1200/JCO.2007.15.4377)
158. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)
159. You YN, Thompson GB, Young WF Jr, Larson D, Farley DR, Richards M & Grant CS 2007 Pancreatoduodenal surgery in patients with multiple endocrine neoplasia type 1: operative outcomes, long-term function, and quality of life. Surgery 142 829-836 (discussion 836 e821). (doi:10.1016/j.surg.2007.09.010)